Skip to main content
71°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bellus Health Inc
(NQ:
BLU
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 28, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bellus Health Inc
< Previous
1
2
3
4
Next >
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
May 17, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
BELLUS Health Reports First Quarter 2022 Financial Results and Business Highlights
May 11, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference
May 02, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Participate in Multiple Upcoming Investor Conferences
April 25, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Reports Year 2021 Financial Results and Business Highlights
February 23, 2022
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States
December 17, 2021
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States
December 14, 2021
From
BELLUS Health Inc.
Via
Business Wire
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
December 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that...
Via
Benzinga
BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States
December 13, 2021
From
BELLUS Health Inc.
Via
Business Wire
58 Biggest Movers From Yesterday
December 14, 2021
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares jumped 80.4% to close at $90.08 on Monday. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-...
Via
Benzinga
Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher
December 13, 2021
Toward the end of trading Monday, the Dow traded down 0.67% to 35,728.62 while the NASDAQ fell 0.92% to 15,487.41. The S&P also fell, dropping 0.58% to 4,684.47. The U.S. has...
Via
Benzinga
Mid-Day Market Update: Nasdaq Drops Over 100 Points; Foghorn Therapeutics Shares Surge
December 13, 2021
Midway through trading Monday, the Dow traded down 0.81% to 35,679.10 while the NASDAQ fell 0.78% to 15,509.01. The S&P also fell, dropping 0.67% to 4,680.56. The U.S. has the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
40 Stocks Moving In Monday's Mid-Day Session
December 13, 2021
Gainers Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) shares climbed 83.4% to $91.52. Pfizer agreed to acquire Arena Pharmaceuticals for $100 per share in an all-cash transaction....
Via
Benzinga
ARNA Stock Alert: The Pfizer Deal That Has Arena Pharmaceuticals Rocketing Today
December 13, 2021
Arena Pharmaceuticals (ARNA) stock is flying higher on Monday thanks to a huge $6.7 billion acquisition deal with Pfizer (PFE).
Via
InvestorPlace
Here's Why Bellus Health Is Jumping Higher Today
December 13, 2021
A phase 2 trial with the company's chronic-cough candidate hit its primary endpoint.
Via
The Motley Fool
NES, WTTR: The Deal That Has Penny Stock Nuverra Environmental Solutions Skyrocketing Today
December 13, 2021
Nuverra Environmental (NES) stock is surging higher on Monday following news of a massive deal with Select Energy Services (WTTR).
Via
InvestorPlace
BLU Stock Alert: The Study Data That Has BELLUS Health Blasting Higher Today
December 13, 2021
BELLUS Health (BLU) stock is rocketing higher on Monday and it's all thanks to data from a Phase 2b clinical trial of BLU-5937.
Via
InvestorPlace
Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals
December 13, 2021
Following the market opening Monday, the Dow traded down 0.65% to 35,736.04 while the NASDAQ fell 0.26% to 15,590.13. The S&P also fell, dropping 0.46% to 4,690.48. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
December 13, 2021
From
BELLUS Health Inc.
Via
Business Wire
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
December 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome...
Via
Benzinga
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
November 10, 2021
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
November 10, 2021
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
November 01, 2021
From
BELLUS Health Inc.
Via
Business Wire
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
September 23, 2021
From
BELLUS Health Inc.
Via
Business Wire
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
September 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...
Via
Benzinga
Exposures
Product Safety
46 Biggest Movers From Yesterday
September 15, 2021
Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share. Onion Global Limited...
Via
Benzinga
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
September 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Exposures
COVID-19
Why BELLUS Health Is Trading Higher Today
September 14, 2021
BELLUS Health (NASDAQ:BLU) shares are trading higher. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic...
Via
Benzinga
Mid-Afternoon Market Update: Dow Tumbles 300 Points; Communications Systems Shares Climb
September 14, 2021
Toward the end of trading Tuesday, the Dow traded down 0.87% to 34,565.88 while the NASDAQ fell 0.46% to 15,035.39. The S&P also fell, dropping 0.60% to 4,441.76. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Mid-Day Market Update: FuelCell Energy Jumps After Q3 Results; RedHill Biopharma Shares Slide
September 14, 2021
Midway through trading Tuesday, the Dow traded down 0.49% to 34,698.16 while the NASDAQ fell 0.05% to 15,098.38. The S&P also fell, dropping 0.24% to 4,458.05. The U.S. has...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.